Key result
Enalaprilat increased the total number of low-affinity bradykinin binding sites on CHO cells expressing both B2 receptor and ACE from 18.4 to 40.3 fmol/10^6 cells (P<0.05).
Absolute Event Rate: 40.3% vs 18.4%
p-value: p=< .05
ACE inhibitors potentiate bradykinin actions beyond blocking its hydrolysis by enhancing binding, protecting high-affinity receptors, blocking desensitization, and decreasing internalization.
May explain ACE inhibitor benefits via bradykinin potentiation; leaves open clinical translation to cardiovascular outcomes.
Part of the beneficial effects of angiotensin I-converting enzyme (ACE) inhibitors are due to augmenting the actions of bradykinin (BK). We studied this effect of enalaprilat on the binding of [3H]BK to Chinese hamster ovary (CHO) cells stably transfected to express the human BK B2 receptor alone (CHO-3B) or in combination with ACE (CHO-15AB). In CHO-15AB cells, enalaprilat (1 mumol/L) increased the total number of low-affinity [3H]BK binding sites on the cells at 37 degrees C, but not at 4 degrees C, from 18.4 +/- 4.3 to 40.3 +/- 11.9 fmol/10(6) cells (P < .05; Kd, 2.3 +/- 0.8 and 5.9 +/- 1.3 nmol/L; n = 4). Enalaprilat preserved a portion of the receptors in high-affinity conformation (Kd, 0.17 +/- 0.08 nmol/L; 8.1 +/- 0.9 fmol/10(6) cells). Enalaprilat decreased the IC50 of [Hyp3-Tyr(Me)8]BK, the BK analogue more resistant to ACE, from 3.2 +/- 0.8 to 0.41 +/- 0.16 nmol/L (P < .05, n = 3). The biphasic displacement curve of the binding of [3H]BK also suggested the presence of high-affinity BK binding sites. Enalaprilat (5 nmol to 1 mumol/L) potentiated the release of [3H]arachidonic acid and the liberation of inositol 1,4,5-trisphosphate (IP3) induced by BK and [Hyp3-Tyr(Me)8]BK. Moreover, enalaprilat (1 mumol/L) completely and immediately restored the response of the B2 receptor, desensitized by the agonist (1 mumol/L [Hyp3-Tyr(Me)8]BK); this effect was blocked by the antagonist, HOE 140. Finally, enalaprilat, but not the prodrug enalapril, decreased internalization of the receptor from 70 +/- 9% to 45 +/- 9% (P < .05, n = 7). In CHO-3B cells, enalaprilat was ineffective. ACE inhibitors in the presence of both the B2 receptor and ACE enhance BK binding, protect high-affinity receptors, block receptor desensitization, and decrease internalization, thereby potentiating BK beyond blocking its hydrolysis.
No takes yet. Share an insight, caveat, or question.
Minshall et al. (1997) studied this question. Enalaprilat was evaluated on Total number of low-affinity [3H]BK binding sites on CHO-15AB cells at 37 degrees C (p=< .05). Enalaprilat increased the total number of low-affinity bradykinin binding sites on CHO cells expressing both B2 receptor and ACE from 18.4 to 40.3 fmol/10^6 cells (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: